Supernus Pharmaceuticals (SUPN) grants director RSUs and stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

GEMAYEL GEORGES reported acquisition or exercise transactions in this Form 4 filing.

Supernus Pharmaceuticals director Georges Gemayel reported receiving new equity awards. On February 18, 2026, he was granted 2,989 restricted stock units and 4,977 director stock options, both at a price of $0.0000 per unit. The RSUs and options each vest on February 18, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GEMAYEL GEORGES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,989	$0.00	--
Grant/Award	Director Stock Option (Right to Buy)	4,977	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 2,989 shares (Direct); Director Stock Option (Right to Buy) — 4,977 shares (Direct)

Footnotes (1)

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Each option vests on February 18, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/20/2026 - 04:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEMAYEL GEORGES

(Last)

(First)

(Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	02/18/2026		A		2,989		⁽²⁾	⁽²⁾	Common Stock	2,989	$0	2,989	D
Director Stock Option (Right to Buy)	$50.2	02/18/2026		A		4,977		⁽³⁾	02/18/2036	Common Stock	4,977	$0	4,977	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.

3. Each option vests on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Supernus (SUPN) director Georges Gemayel receive?

Georges Gemayel received 2,989 restricted stock units and 4,977 director stock options. Both awards were granted at a price of $0.0000 per unit, representing compensation rather than open-market purchases of Supernus common stock.

When do Georges Gemayel’s Supernus (SUPN) restricted stock units vest?

The restricted stock units granted to Georges Gemayel vest on February 18, 2027. Each restricted stock unit represents the right to receive one share of Supernus common stock when it vests and is then settled in common stock.

What is the vesting schedule for Georges Gemayel’s Supernus (SUPN) stock options?

The director stock options granted to Georges Gemayel fully vest on February 18, 2027. After vesting, the options represent the right to buy Supernus common stock under the terms of the option award.

Does Georges Gemayel’s Form 4 for Supernus (SUPN) show any stock sales?

No, the Form 4 reports only acquisitions through grants of restricted stock units and director stock options. There are no reported sales or dispositions of Supernus common stock or derivative securities in this filing.

How many Supernus (SUPN) restricted stock units does Georges Gemayel hold after this grant?

After the reported grant, Georges Gemayel holds 2,989 restricted stock units. These units will be settled in shares of Supernus common stock once they vest on February 18, 2027, according to the filing footnotes.

How many Supernus (SUPN) director stock options does Georges Gemayel hold after this grant?

Following the grant, Georges Gemayel holds 4,977 director stock options. These options vest on February 18, 2027 and give him the right to buy Supernus common stock once the vesting condition is satisfied.